Australian Patent Office Grants Geron's Nuclear Transfer Patents Following Withdrawal of Oppositions.Business Editors/Health/Medical Writers MENLO PARK Menlo Park. 1 Residential city (1990 pop. 28,040), San Mateo co., W Calif.; inc. 1874. Electronic equipment and aerospace products are manufactured in the city. Menlo College and a Stanford Univ. research institute are there. 2 Uninc. , Calif.--(BUSINESS WIRE)--March 5, 2003 Geron Corporation (Nasdaq:GERN v. t. 1. To grin or yawn. ) announced today that the Australian Patent Office has granted two patents for the fundamental nuclear transfer technology that was first invented at the Roslin Institute and is now used worldwide for the cloning of animals. Geron holds exclusive rights to this technology for a broad range of commercial applications and has licensed the patents to a number of companies involved in animal cloning. The two new patents -- 716956 and 728809 -- were first approved for grant by the Australian Patent Office in 2000. Under Australian law, other parties can challenge the grant of a patent through an opposition procedure. In this instance, both patents were challenged by Monash University Facilities in are diverse and vary in services offered. Information on residential sevices at Monash University, including on-campus (MRS managed) and off-campus, can be found at [2] Student organisations and the Dairy Research & Development Corporation. However, one opposition was withdrawn after Geron and Roslin filed evidence rebutting arguments made by the opponents, and the second was withdrawn shortly thereafter. "We are very pleased with this result," noted David J David J. Haskins (b. April 24, 1957, in Northampton, England) is a British alternative rock musician. He was the bassist for the seminal gothic rock band Bauhaus. Life and work . Earp, J.D., Ph.D., Geron's vice president of intellectual property. "It confirms our belief -- and that of our licensees -- in the strength of these patents. The technology that they cover is fundamental to the science of animal cloning, and it has been successfully used to clone many animal species including cattle, sheep, pigs, goats, rabbits and mice." Geron has granted licenses under the patents for the use of this technology in agricultural and bio-manufacturing applications. Patents have now been issued in several jurisdictions, including the U.S., the U.K., Europe, New Zealand New Zealand (zē`lənd), island country (2005 est. pop. 4,035,000), 104,454 sq mi (270,534 sq km), in the S Pacific Ocean, over 1,000 mi (1,600 km) SE of Australia. The capital is Wellington; the largest city and leading port is Auckland. , South Africa, Hong Kong and Singapore. Geron is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutic and diagnostic products for applications in oncology and regenerative medicine, and research tools for drug discovery. Geron's product development programs are based upon three patented core technologies: telomerase telomerase /telo·mer·ase/ (te-lo´mer-as) a DNA polymerase involved in the formation of telomeres and the maintenance of telomere sequences during replication. te·lom·er·ase n. , human embryonic stem cells and nuclear transfer. This news release may contain forward-looking statements made pursuant to the "safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Investors are cautioned that such forward-looking statements in this press release regarding future applications of Geron Corporation's technology constitute forward-looking statements involving risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, need for additional capital, need for regulatory approvals or clearances, and the maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Geron's periodic reports, including the annual report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2002. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion